"tuberculosis-vaccine"

The clinical trials are being carried out by Bharat Biotech in collaboration with Biofabri, the noted vaccine developer from Spain.

Mtbvac is being developed for two purposes; firstly, as a more effective and potentially longer-lasting vaccine than BCG ( Bacillus Calmette Guérin) for newborns and secondly, for the prevention of TB in adults and adolescents, for whom there is currently no effective vaccine.

Previous studies have reported that BCG vaccination may confer protection against respiratory tract infections, involving viral infections.

In the new study, published in The Journal of Clinical Investigation, the research team tested the blood of more than 6,000 healthcare workers for evidence of antibodies to SARS-CoV-2.